Human nhe2
CA 2400531 A1 · Owner: Pfizer Products Inc. · Inventors: Sun, Dexue; Kennedy, Scott Paul
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention is directed to two forms of isolated or purified human NHE2 polypeptide sequences, NHE2-LF and NHE2-SF as well as the polynucleotide , coding sequences that encode the human NHE2-LF and NHE2-SF polypeptides. Also featured are NHE2-LF- and NHE2-SF-related hosts cell membrane preparations, vectors, and antibodies as well as methods of using cells recombinantly expressing, the human NHE2-LF or NHE2-SF to identify agents that modulate human NHE activity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 29, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.